A 55-year-old with a palpable mass in the right breast

Last updated: May 6, 2026Bookmark

History

A 55-year-old post-menopausal woman presents with a new breast mass in her right breast.

Q1: What is the significance of her age in this case?

She is post-menopausal. Breast carcinoma can occur at any age but frequency increases at 40 years. A new breast mass in a post-menopausal woman is cancer unless stated otherwise. She is less likely to be affected by masses that affect premenopausal women such as fibroadenoma and fibrocystic disease.

Q2: For her history of the presenting complaint, what information would you like to know about the new breast mass?
  • Location of the mass
  • Since when has the mass been present
  • Rate of growth: rapid vs gradual
  • Is the mass painful?
  • Is the mass ulcerated?
  • Are there any other skin changes?
  • Does the mass shift position within the breast?
  • Is there nipple retraction?
  • Is there nipple discharge?
  • Is there a mass in the opposite breast?
  • Common causes of breast pain include: the luteal phase of the menstrual cycle, pregnancy, hematoma, cysts, mastitis, abscess, galactocele, and nipple fissure Malignant masses are commonly painless Hard fibroadenoma AKA breast mouse is commonly associated with shifting position Swelling found in both breasts include fibroadenoma, fibrocystic change and 3% of breast carcinoma

She states that the mass has been there for about 3 months and has slowly grown in size. She first noticed it when she was taking a shower. The mass is not painful. She reports no nipple discharge, no nipple inversion, and no skin changes.

Q3: What questions would you ask her to determine the likely cause of the breast mass?

All breast masses that persist through one complete menstrual cycle, and all masses in post-menopausal women require evaluation. Remember that a normal mammogram or non-visualization of a palpable mass by ultrasound does not exclude cancer

There is a 5x risk for breast carcinoma with a family history of breast or ovarian cancer. Additionally, there is a very high risk of BRCA1 and BRCA2 mutations

Nulliparous women and women who do not breastfeed have an increased risk of breast cancer

She had her first menstrual period at 11 years of age. Her only pregnancy was at 35 years of age. Her mother and sister both had breast cancer.

Q4: What additional symptoms do you need to rule out that would suggest that the breast mass is “complicated”?
  • History of Fever
  • History of Purulent Discharge
  • History of weight loss
  • History of swelling in the armpits or neck
  • History of shoulder pain, back pain, or abdominal swelling
  • History of coughing up blood or breathlessness
  • History of yellow discoloration of the eyes
  • History of weakness, impaired sensation, headache, or blurry vision
  • Fever, pain, and purulent discharge would indicate an infective process

Physical Examination

You proceed to perform a physical examination, starting with an inspection of the breasts.

Q5: How should the patient be positioned to properly inspect the breasts?
  • Sitting with hands on the hips
  • Sitting with hands overhead
  • Supine with hands overhead

The best time to examine the breast is 5 to 7 days after the onset of menses. The breasts may be engorged before menses, and during pregnancy making examination more painful and less accurate.

Both breasts are examined sequentially both sitting and supine

Pressing the hands on the hips may bring out dimpling by putting tension on the breast ligaments arising from the pectoralis major fascia

Raising the hands overhead stretches the ligaments of Cooper causing the skin or nipples to retract. It also allows us to expose the undersurface of the breast and examine the axilla

Q6: What findings are you looking for on inspection of the breasts?

Inspection of the breast

  • Compare breast position
  • Obvious mass
  • Visible swelling in the axilla or neck
  • Swelling of the arms

Swelling of the arms may due to lymphatic spread, post-operative axillary vein thrombosis or lymphedema following radical lymphadenectomy of the axillary nodes

Inspection of the skin over the breast

  • Ulceration
  • Dimpling or retraction
  • Peau d’ orange
  • Dilated veins

Ulceration is seen in a fungating carcinoma, cystosarcoma phyllodes and a rapidly growing fibroadenoma due to pressure atrophy

Try to pass a probe beneath the skin. It is possible to do so in benign conditions but impossible in malignancy

Peau d’Orange is a pitted appearance caused by cutaneous edema. The pitted marks are attachments or openings of follicles and sweat glands where the skin is firmly attached. It is seen in inflammatory carcinoma due to blockage of the lymphatic ducts.

Dilated veins may indicate Mondor’s disease, a huge abscess, phyllodes tumor or sarcoma

Inspection of the nipples

  • The presence or absence of nipples
  • Position
  • Number
  • Retraction
  • Cracks and Fissures
  • Discharge

Circumferential retraction may indicate breast cancer – the tumor infiltrates and shortens major ducts causing retraction Slit-like retraction may indicate duct ectasia w/ periductal mastitis Bilateral nipple retraction may be congenital Unilateral nipple retraction may indicate carcinoma or may follow fibrosis of a chronic abscess For discharge ask the patient to express. Also check whether retraction reverts as the attempt to express.

Inspection of the Areola

  • Redness
  • Shininess
  • Oedema

Differentiate between eczema and Paget’s disease when examining the Areola Paget’s disease is Unilateral and occurs commonly in older women, there is no itching and vesicles and there may be destruction of the nipple and underlying lump Eczema is bilateral and occurs commonly in younger women. There is itching and vesicles. There is no destruction of the nipple and underlying lump. Unlike Paget’s disease, it has a quick response to local steroids

Q7: How should the patient be positioned to properly palpate the breast?

Bimanual palpation should be performed with the patient lying supine with the ipsilateral arm raised above her head

Q8: What findings are you looking for while palpating the breasts?

Palpation of both breasts

  • Locate the mass
  • Warmth
  • Tenderness

Palpation of the mass

  • Number of masses
  • Location
  • Size in 3 dimensions
  • Shape
  • Margins
  • Consistency
  • Fluctuation
  • Tenderness
  • Fixity to skin
  • Fixity to breast tissue
  • Fixity to chest wall

Mass with irregular surface and ill-defined margins may indicate breast carcinoma

Mass with well-defined margins and globular in shape are benign processes such as breast cysts and fibroadenoma

A cyst is a collection of fluid in a cavity lined by epithelium or endothelium

Breast cysts are fluctuant. They can also occur in fibroadenomas, cystic degeneration in malignancy, chronic abscesses

Fibromas have a firm consistency

Fibroadenomas are hard and feel like a pellet (diffuse shotty feel)

Carcinomas are usually hard to stony hard

Cysts, lipomas, and abscesses are soft in consistency

For fixity, pinch the skin over the mass and see whether it moves. Breast cancer, traumatic fat necrosis, and chronic abscesses are usually firmly tethered to the skin

Palpation of the axilla

  • Lymphadenopathy
  • Are the lymph nodes discrete or matted?
  • Are there fixed or mobile lymph nodes?
  • Is there tenderness?
  • What is the consistency of the lymph nodes?

Group I nodes: Pectoral, Subscapular, Brachial

Group II nodes: Interpectoral, Central

Group III nodes: apical and supraclavicular

With the shoulder adducted, forearm flexed and resting over your forearm

Push fingers as high as possible to palpate the central nodes

Run fingers against the anterior axillary fold to palpate pectoral nodes

Run fingers against the humerus to palpate the brachial nodes

Stand behind the patient and run fingers against the posterior axillary fold to palpate the subscapular node

Then palpate the deltopectoral grove and superior to the middle 1/3 of the clavicle

On physical examination, she has a 2cm palpable, hard, ill-defined, immobile, non-tender mass in the upper outer quadrant of her right breast. There is no palpable axillary or supraclavicular lymphadenopathy.

Q9: What are the differentials for a benign palpable breast mass?
  • Fibrocystic change: lumpy breast, upper quadrant, blue-dome appearance of cysts in physical exam
  • Fibroadenoma: well-circumscribed mobile, rubbery, encapsulated mass
  • Intraductal papilloma: unilateral blood nipple discharge in premenopausal women
  • Fat necrosis: trauma to the breast or breast surgery, accompanied by pain
  • Abscess: painful mass in lactating breast, erythematous and warm, fever, purulent discharge from the mass or nipple
  • Galactocele: painful or painless aseptic mass in lactating breast, neither warm nor erythematous
Q10: What are the differentials for a malignant palpable breast mass?
  • Ductal carcinoma in situ: not palpable
  • Invasive ductal carcinoma: firm, immobile, discrete mass, nipple retraction, painless
  • Invasive lobular carcinoma: firm, immobile, discrete mass, nipple retraction, painless, frequently bilateral
  • Mucinous carcinoma: gelatinous well-circumscribed mass
  • Inflammatory carcinoma: inflamed, tender, warm, erythematous breast, peau d’orange
  • Phyllodes tumor: mobile, slow-growing, firm, rubber, and large
Q11: What is the most likely diagnosis for this woman?
  • Invasive Breast Cancer
    • Post-menopausal woman with new palpable breast mass
    • Her risk factors for breast cancer include a family history in a first-degree relative and early menarche
    • The mass is non-tender, hard, ill-defined, immobile, and in the upper outer quadrant

Investigations

Q12: What investigations would you perform to confirm the diagnosis, grade, and classify the tumor?
  • Mammography
  • Core needle biopsy

This is part of the triple assessment of breast cancer – physical examination, imaging, tissue sample for pathology

Imaging is done to rule out malignancy, and multicentricity and to screen women older than 30 years

Mammography is generally for women > 35 years and ultrasound < 35 years due to denser breast tissue. Ultrasound can also be used for needle-guided aspiration

FNAC is performed for cystic masses that are painful or enlarging

MRI is not indicated for the workup of a new breast mass due to its high false-positive rate

Q13: What imaging findings on mammography are suspicious of malignancy?
  • Asymmetry
  • Clustered pleomorphic calcifications
  • Increasing density
  • New mass with irregular borders or spiculations
Q14: What investigations would you perform following the diagnosis of breast cancer?

Metastatic workup

  • Liver Function Test: for liver metastasis
  • Alkaline phosphatase and serum calcium: for bone metastasis
  • Chest X-ray: for pulmonary metastasis

Further Investigations for metastasis

  • Abdominal and Chest CT: if abnormal chest X-ray and laboratory values
  • Bone scintigraphy: suspicious bone pain or abnormal bone studies
  • Brain CT or MRI: new onset headache, visual changes, or seizures
  • PET scan

Treatment

Q15: What surgical options are available for a patient with Stage I and II Breast cancer
  • Breast-Conserving Therapy (BCT): Lumpectomy (Partial Mastectomy) + Sentinel Lymph Node Biopsy (SLNB; 2-4 nodes) + Radiation (to decrease risk of local recurrence)
    • Equal survival to mastectomy
    • High local recurrence rate
  • Simple Mastectomy with SLNB only
    • Radiation is not needed in early stage
Q16: What are the surgical options for clinically advanced stage 3 breast cancer

  • Simple mastectomy: if a large primary tumor
  • Simple mastectomy with axillary lymph node dissection (SLND): if nodes are enlarged and matted
  • Modified radical mastectomy (Mastectomy + ALND)
  • Neoadjuvant chemotherapy followed by Modified radical mastectomy, then irradiation: for inflammatory breast cancer
Q17: What are the contraindications to BCT

Absolute contraindication

  • Multiple primary tumors in 2 or more quadrants
  • Diffuse malignant microcalcifications throughout the breast
  • History of chest wall irradiation
  • Positive margins despite repeat excision
  • Early pregnancy (radiation cannot be given during pregnancy)
Q18: What are the options for hormonal therapy
  • Estrogen Receptor Blockers: Tamoxifen, Raloxifene, Fulvestrant
  • Aromatase inhibitors: Anastrozole
  • HER2/Neu Receptor blocker: Trastuzumab
Q19: What drug classes are used for chemotherapy in breast cancer?
  • Anthracyclines: Doxorubicin, epirubicin, idarubicin
  • Alkylating agent: Cyclophosphamide
  • Antimetabolites: Methotrexate, 5-FU
  • Taxanes: Paclitaxel, Docetaxel
Q20: Which patients do not need chemotherapy?
  • Carcinoma in situ
  • Small (<1 cm) tumor with favorable hormonal and molecular characteristics
  • SLNB negative

Complications

Q21: What nerves are at risk of damage during dissection
  • Long thoracic
  • Thoracodorsal
  • Medial pectoral
  • Lateral pectoral
Q22: What is the most severe complication of lymph node dissection
  • Lymphedema
    • ALND is associated with a greater risk of lymphedema than SLNB
  • Lymphangiosarcoma in chronic cases (Stuart Treves syndrome)
    • Has a poor prognosis even after limb amputation

This is why SLNB is very useful. It prevents unnecessary ALND

Key Learning Points

  • New breast masses in post-menopausal women should be considered malignant until proven otherwise.
  • Thorough history should include mass characteristics, associated symptoms, menstrual/reproductive history, and family history of breast/ovarian cancer.
  • Proper physical examination technique is crucial, including inspection and palpation in different patient positions.
  • The triple assessment for breast masses includes physical examination, imaging, and tissue sampling.
  • Differentiate between benign and malignant causes of breast masses based on clinical features.
  • Treatment options vary based on cancer stage, ranging from breast-conserving therapy to mastectomy with lymph node management.
  • Consider contraindications to breast-conserving therapy when planning treatment.
  • Be aware of potential surgical complications, especially lymphedema following axillary lymph node dissection.
  • Adjuvant therapies include radiation, hormonal therapy, and chemotherapy, with selection based on tumor characteristics and stage.
  • Sentinel lymph node biopsy can help avoid unnecessary axillary lymph node dissection in early-stage cancers.
Reference Intervals
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator

Leave a Reply

A moment of your time
Step 1 of 2

You are the reason this exists. Got 60 seconds? Help us improve Hyperexcision for every medical student who uses it.

The Hyperexcision Team